Aubrey de Grey: revision 1 to 3

Revision 1

Revision 3

categories: ["people", "longevity"]

tags: ["aging", "sens", "biogerontology", "life extension", "rejuvenation", "advocacy"]

summary: "British biogerontologist who proposed the SENS damage-repair framework for rejuvenation and popularized the idea of longevity escape velocity."

summary: "British biogerontologist who proposed the SENS damage-repair framework for rejuvenation and popularized the idea of longevity escape velocity."

updated: "2026-07-27"

updated: "2026-10-29"

issues: ["The 2021 misconduct section carries no citation for the investigation or its outcome."]

---

```infobox

**Aubrey de Grey** is a British biogerontologist who argues that aging should be treated as a

finite set of accumulated molecular and cellular lesions that periodic repair can remove, rather

than as a metabolic process that medicine must learn to slow. He formalized that position as SENS

— Strategies for Engineered Negligible Senescence — and popularized the term

(Strategies for Engineered Negligible Senescence) and popularized the term

[[longevity-escape-velocity]]. He is the most visible advocate of radical life extension and among

the most heavily criticized figures in the field.

## Overview

De Grey's importance is organizational and rhetorical more than experimental. He has run almost no

wet-lab research of his own, and his primary contribution is a framework: a claim that the damage

wet-lab research of his own. His primary contribution is a framework, which claims that the damage

accumulated during aging falls into a small number of categories, that each category has a

conceivable repair strategy, and that the list is complete enough to serve as an engineering

specification. Mainstream biogerontology has largely accepted his framing question — whether aging

specification. Mainstream biogerontology has largely accepted his framing question, whether aging is

is tractable at all — while rejecting his timelines and much of his confidence.

tractable at all, while rejecting his timelines and much of his confidence.

## Career

[[sens-research-foundation]] in California, and later committed a substantial personal inheritance

to it and to allied organizations. The foundation funded work on lysosomal enzymes for

[[proteostasis|aggregate clearance]], allotopic expression of mitochondrial genes, and immune

approaches to [[cellular-senescence|senescent cells]] — several years before [[senolytics]] became

approaches to [[cellular-senescence|senescent cells]], several years before [[senolytics]] became

a mainstream target.

## SENS and the damage-repair thesis

The name is borrowed from comparative biology: a species shows

The name is borrowed from comparative biology: a species shows [[negligible-senescence]] when its

[[negligible-senescence]] when its mortality rate does not rise measurably with age. SENS

mortality rate does not rise measurably with age. SENS proposes to engineer that condition rather

proposes to engineer that condition rather than find it. It partitions age-related damage into

than find it. It partitions age-related damage into seven categories: cell loss and atrophy,

seven categories: cell loss and atrophy, cancerous

cancerous mutations, [[mitochondrial-dysfunction|mitochondrial DNA mutations]], death-resistant cells,

mutations, [[mitochondrial-dysfunction|mitochondrial DNA mutations]], death-resistant cells,

extracellular crosslinks, extracellular aggregates, and intracellular aggregates. For each, de Grey

proposes a repair rather than a prevention: replace lost cells with

[[induced-pluripotent-stem-cells|stem-cell derivatives]], remove senescent cells, back up

> [!key] Why the framing matters

> Damage repair is agnostic about the causes of aging. If the categories are complete, a therapy

> works even if nobody knows why the damage forms — the same logic by which a mechanic restores a

> works even if nobody knows why the damage forms, in the way a mechanic restores a car without a

> car without a theory of corrosion. The whole argument rests on completeness, which is exactly what

> theory of corrosion. The whole argument rests on completeness, and completeness is what critics

> critics dispute.

> dispute.

The scheme predates and partly overlaps the [[hallmarks-of-aging]] taxonomy published in 2013, and

the two are often compared. The hallmarks are a consensus classification derived from experimental

treated person enough additional years for the next generation to arrive, remaining life expectancy

stops falling. He has repeatedly given roughly even odds of reaching that threshold within a

decade or two, conditional on funding, and has said that the first person to live past 1,000 may

already be born — a claim that sits far outside anything the record of

already be born. That claim sits far outside anything the record of

[[maximum-human-lifespan|documented human longevity]] supports. No demographic or biological

evidence establishes a date, and de Grey presents these as conditional forecasts rather than

projections from data. The framing has the useful property of shifting attention from

projections from data. One useful effect of the framing is that it shifts attention from

[[healthspan|how long people stay well]] to the rate at which therapies improve.

## Reception

any molecular biologist who could demonstrate that SENS was too wrong to merit debate. A panel

including Craig Venter, Nathan Myhrvold and Rodney Brooks concluded in 2006 that no submission met

that bar, while also finding SENS highly speculative and largely unsupported by reproducible

results; a critique led by Preston Estep received a partial award.[^tr2006] The verdict has been

results; a critique led by Preston Estep received a partial award.[^tr2006] Both sides have cited

cited by both sides ever since — as vindication that SENS is not pseudoscience, and as confirmation

the verdict ever since, one as vindication that SENS is not pseudoscience and the other as

that it is unproven.

confirmation that it is unproven.

A 2005 *EMBO Reports* commentary signed by a large group of biogerontologists, including Steven

Austad and Huber Warner, argued that none of the SENS proposals had been shown to work in a mammal

and that presenting them as a near-term engineering plan misrepresented the state of the

science.[^warner2005] That remains the mainstream position: the categories are a useful checklist,

science.[^warner2005] That remains the mainstream position. The categories are a useful checklist,

the timelines are not credible, and the gap between a mouse result and a human therapy is

systematically understated.

## Departure from SENS Research Foundation

In August 2021, two women in the longevity field publicly described inappropriate conduct by de

In August 2021, Laura Deming, founder of the Longevity Fund, and Celine Halioua, chief executive

Grey. The SENS Research Foundation placed him on leave, commissioned an independent legal

of the biotech company Loyal, publicly described sexual harassment by de Grey when they were young

investigation, and terminated his employment. De Grey denied wrongdoing and disputed the process.

scientists entering the field. STAT reported that the SENS Research Foundation placed him on leave

The episode split the organization and its donor base, and prompted broader discussion of conduct

pending an independent investigation, and that de Grey denied the allegations.[^stat2021] Later

norms in a field that depends heavily on a small number of private funders.

that month the foundation removed him as chief science officer, saying he had attempted to

interfere with the investigation.[^stat2021b] In September 2021 the investigating law firm, Van

Dermyden Makus, released an executive summary finding that he had made offensive sexual comments

to the two women; the foundation's board called the behaviour described unacceptable and

apologised to those affected.[^stat2021c] De Grey continued to dispute the findings and the

process. The episode split the organization and its donor base, and prompted broader discussion of

conduct norms in a field that depends heavily on a small number of private funders.

## Legacy and current work

Since 2022 de Grey has led the Longevity Escape Velocity Foundation, whose main programme is the

Since late 2022 de Grey has led the Longevity Escape Velocity Foundation, announced at the

Robust Mouse Rejuvenation study: rather than testing single compounds, it combines interventions

Longevity Summit Dublin that year.[^levf] Its main programme is the Robust Mouse Rejuvenation

already reported individually to extend mouse lifespan — [[rapamycin]] among them — and starts them

series. Rather than testing single compounds, the first study combined four interventions already

in middle age, asking whether the effects add. That design addresses a real gap, since the field has

reported individually to extend mouse lifespan ([[rapamycin]], a senolytic, telomerase gene

run very few combination studies, and its results, whatever they show, are more checkable than any

therapy and hematopoietic stem-cell transplantation), starting at eighteen months of age, to ask

of his forecasts.

whether the effects add.[^lt2022] The design addresses a real gap, since the field has run very

few combination studies, and its results, whatever they show, are more checkable than any of his

forecasts.

His durable influence is that he moved the question. Arguments that aging research was intrinsically

His durable influence is on which questions are asked. Arguments that aging research was

disreputable were common when he began; the [[geroscience-hypothesis]] is now respectable enough to

intrinsically disreputable were common when he began; the [[geroscience-hypothesis]] is now respectable enough to

be discussed with regulators, and senolytics, [[epigenetic-reprogramming]] and

[[aging-biomarkers]] are funded programmes at major institutions. Whether that shift is

[[aging-biomarkers]] are funded programmes at major institutions. Whether he caused that shift or

attributable to him or merely coincident with him is contested. What is not contested is that the

merely coincided with it is contested. It is not contested that the therapies he described in 2005

therapies he described in 2005 as achievable within decades remain, twenty years on, unavailable in

as achievable within decades remain, twenty years on, unavailable in any clinic.

any clinic.

## See also

[^ea2007]: `book` de Grey, A. and Rae, M. *Ending Aging: The Rejuvenation Breakthroughs That Could Reverse Human Aging in Our Lifetime*. St. Martin's Press, 2007. {A trade book by the subject setting out his own programme; it argues that the repairs are feasible rather than reporting results.}

[^ea2007]: `book` de Grey, A. and Rae, M. *Ending Aging: The Rejuvenation Breakthroughs That Could Reverse Human Aging in Our Lifetime*. St. Martin's Press, 2007. {A trade book by the subject setting out his own programme; it argues that the repairs are feasible rather than reporting results.}

[^tr2006]: `news` Pontin, J. "Is Defeating Aging Only a Dream?" *Technology Review* SENS Challenge report, 2006.

[^warner2005]: `paper` Warner, H. et al. "Science fact and the SENS agenda: What can we reasonably expect from ageing research?" *EMBO Reports*, 2005. {A signed commentary by a group of biogerontologists rather than a research paper; it reports their judgment of the SENS proposals.}

[^warner2005]: `paper` Warner, H. et al. "Science fact and the SENS agenda: What can we reasonably expect from ageing research?" *EMBO Reports*, 2005. {A signed commentary by a group of biogerontologists rather than a research paper; it reports their judgment of the SENS proposals.}

[^stat2021]: `news` Molteni, M. "Anti-aging research pioneer Aubrey de Grey placed on leave over sexual harassment allegations." *STAT*, 11 August 2021. {Reports the public accounts by Deming and Halioua, the foundation's decision to place de Grey on leave, and his denial.}

[^stat2021b]: `news` "SENS Research Foundation removes Aubrey de Grey over concerns he was interfering in sexual harassment investigation." *STAT*, August 2021.

[^stat2021c]: `news` Molteni, M. "Scientist Aubrey de Grey made inappropriate sexual comments to two female entrepreneurs, independent investigation finds." *STAT*, 11 September 2021. {Reports the release of the investigation's 18-page executive summary by the law firm Van Dermyden Makus and the board's response.}

[^levf]: `statement` Longevity Escape Velocity Foundation, levf.org. {The foundation's own description of itself and of Robust Mouse Rejuvenation as its flagship study; it is the claim of the organization de Grey leads, not independent reporting.}

[^lt2022]: `news` "Robust Mouse Rejuvenation project details announced." *Longevity.Technology*, December 2022. {A trade-press report of the study design: rapamycin, a senolytic, mTERT telomerase gene therapy and hematopoietic stem-cell transplantation, begun in 18-month-old mice at Ichor Life Sciences.}